Amyloidosis Therapeutics Market to Reach Over US$ 6.3 Bn by 2035, Expanding at 8.2% CAGR | Latest Report TMR

The global amyloidosis therapeutics market was valued at US$ 2.7 Bn in 2024 and is estimated to grow at a CAGR of 8.2% from 2025 to 2035, reaching more than US$ 6.3 Bn by the end of 2035. Amyloidosis is a rare and potentially life-threatening disorder characterized by the accumulation of abnormal amyloid protein deposits in organs and tissues, which can impair their normal functioning.

👉 Get sample market research report copy now@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86469

Growing disease awareness, improvements in diagnosis, rising healthcare expenditure, and increasing investment in innovative treatment approaches are supporting the expansion of the market. Pharmaceutical and biotechnology companies are also focusing on targeted therapies designed to address the underlying mechanisms of different forms of amyloidosis.

Market Overview

The amyloidosis therapeutics market is comparatively new but is expanding steadily due to improvements in disease recognition, diagnostic capabilities, and treatment options. Greater awareness of rare diseases is encouraging patients to seek specialized medical care, while healthcare professionals are becoming better equipped to identify the signs and symptoms associated with amyloidosis.

The growing prevalence of chronic conditions associated with amyloidosis, including multiple myeloma and chronic inflammatory diseases, is further increasing demand for effective therapies. At the same time, pharmaceutical companies are investing in innovative drug formulations and disease-specific treatment strategies.
Research and development activities are contributing to the introduction of therapies that can potentially improve patient outcomes. The market is also benefiting from growing patient advocacy, increased funding for rare disease research, and collaborations among biotechnology companies, pharmaceutical manufacturers, hospitals, and research institutions.

Key Drivers of Market Growth

Increasing Prevalence of Amyloidosis
The rising incidence and diagnosis of amyloidosis across different demographic groups represents a major driver of market growth. Light-chain amyloidosis (AL) and other forms are increasingly being identified as healthcare providers improve their ability to recognize disease symptoms and use advanced diagnostic techniques.

According to Immix Biopharma, the estimated U.S. prevalence of relapsed or refractory disease was approximately 29,712 cases in 2023. In addition, an amyloidosis indication review published by the Council of Health Insurance estimates that approximately 4,000 people in the U.S. develop AL amyloidosis each year. Although AL amyloidosis is commonly diagnosed between 50 and 65 years of age, younger individuals can also develop the disease.

Greater patient awareness and support from advocacy organizations are encouraging earlier diagnosis and treatment. This is increasing the number of patients receiving therapy and creating demand for more effective and specialized treatment options.

Rising Investments in Research and Development Activities
Increasing investment in research and development is another significant factor supporting the amyloidosis therapeutics market. Pharmaceutical companies, biotechnology firms, and government organizations are allocating resources toward novel medicines, diagnostic technologies, molecular therapies, and personalized treatment approaches.

Companies are increasingly exploring therapies that target amyloid formation and deposition at the molecular level. For instance, in November 2024, Intellia Therapeutics, Inc. announced positive clinical data from its Phase 1 trial of nexiguran ziclumeran, a potential one-time treatment for ATTR amyloidosis. Development and commercialization of the therapy are being conducted by Intellia as part of a multi-target collaboration with Regeneron.

Key Players and Industry Leaders

The amyloidosis therapeutics market is characterized by the presence of established pharmaceutical companies and emerging biotechnology firms. Major participants are focusing on product development, strategic partnerships, clinical research, regulatory approvals, and geographic expansion.

Prominent companies include Pfizer Inc., Johnson & Johnson Services, Inc., GSK plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Bristol-Myers Squibb Company, Alnylam Pharmaceuticals, Inc., AstraZeneca, BridgeBio Inc., Ionis Pharmaceuticals, Attralus, Inc., and Eisai Co., Ltd.

Key Trends for the Future

A major trend in the market is the growing focus on targeted and disease-modifying therapies. Monoclonal antibodies currently represent a leading drug type because of their ability to selectively target disease-related proteins or deposits and support immune-mediated clearance.

The development of RNA interference therapies and transthyretin-targeting medicines is also transforming the treatment landscape. Self-administered therapies and potentially one-time genetic medicines could further change how ATTR amyloidosis is managed.

AL amyloidosis remains a major application segment because of its substantial disease burden and potentially severe consequences when left untreated. It accounts for approximately 70% of systemic amyloidosis cases globally, according to the provided market information.

Explore our report to uncover in-depth insights - https://www.transparencymarketresearch.com/amyloidosis-therapeutics-market.html

New Opportunities and Challenges

The market presents significant opportunities through the development of novel therapies for underserved patient populations. Advances in molecular biology, RNA interference, gene editing, biomarker development, and precision medicine could enable more effective approaches to disease management.

Expansion of healthcare infrastructure in emerging economies and greater awareness of rare diseases may also create new opportunities for market participants.

However, challenges remain, including the rarity and complexity of amyloidosis, difficulties associated with early diagnosis, high treatment costs, regulatory requirements, and the need for specialized clinical expertise. Limited patient populations can also make clinical trials and commercialization challenging.

Future Outlook

The amyloidosis therapeutics market is expected to maintain strong growth through 2035, supported by increasing disease awareness, improved diagnosis, expanding research programs, and the introduction of innovative therapies.

North America currently represents the leading regional market due to advanced healthcare infrastructure, strong research capabilities, high disease awareness, the presence of major pharmaceutical companies, and supportive regulatory frameworks. Europe and Asia Pacific are also expected to provide important growth opportunities as healthcare access improves and awareness of rare diseases increases.

The continued development of RNA interference therapies, monoclonal antibodies, transthyretin stabilizers, and potentially gene-editing approaches is expected to broaden treatment options and strengthen the competitive landscape.

Market Segmentation

The amyloidosis therapeutics market can be segmented as follows:

By Drug Type: Monoclonal Antibodies, Proteasome Inhibitors, Immunomodulators, Corticosteroids, Alkylating Agents, Transthyretin Stabilizers, and Others including RNA Interference Therapeutics and non-steroid anti-inflammatory drugs.

By Indication: AL (Primary) Amyloidosis, AA (Secondary) Amyloidosis, and Familial ATTR Amyloidosis.

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.

By Region: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Key countries covered include the U.S., Canada, Germany, the U.K., France, Italy, Spain, China, India, Japan, Australia & New Zealand, Brazil, Mexico, GCC countries, and South Africa.

👉 To buy this comprehensive market research report, click here to inquire@ https://www.transparencymarketresearch.com/checkout.php?rep_id=86469<ype=S

Important FAQs with Answers

1. What was the size of the amyloidosis therapeutics market in 2024?
The market was valued at approximately US$ 2.7 Bn in 2024.

2. What is the expected market size by 2035?
The market is projected to reach more than US$ 6.3 Bn by 2035.

3. What is the expected CAGR of the market?
The market is estimated to grow at a CAGR of 8.2% between 2025 and 2035.

4. What is driving market growth?
Increasing prevalence and diagnosis of amyloidosis, rising R&D investments, improved healthcare infrastructure, and the development of targeted therapies are key growth drivers.

5. Which drug type dominates the market?
Monoclonal antibodies represent a leading drug type due to their targeted mechanisms and disease-modifying potential.

More Trending Reports by Transparency Market Research -

Veterinary Imaging Market: https://www.transparencymarketresearch.com/veterinary-imaging-market.html

Medical Billing Outsourcing Market: https://www.transparencymarketresearch.com/medical-billing-outsourcing-market.html

North America Cosmetic Surgery Market: https://www.transparencymarketresearch.com/north-america-cosmetic-surgery-market.html

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact:

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Sales Inquiries: sales@transparencymarketresearch.com
Media Inquiries: media@transparencymarketresearch.com

This release was published on openPR.